Does insurance cover ketamine therapy?

It depends on the form. Spravato (esketamine nasal spray by Janssen) is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. Most major insurers — including Medicare, Medicaid, Aetna, Cigna, UnitedHealthcare, and Blue Cross Blue Shield — cover Spravato with prior authorization. IV ketamine infusions are a different story: IV ketamine is not FDA-approved for depression (it is approved for anesthesia), so it is typically administered off-label. Most insurers do not cover off-label IV ketamine infusions, though some have been making exceptions with prior authorization. Out-of-pocket IV ketamine typically runs $400–$800 per infusion, with a standard course being 6 infusions.

Does insurance cover psilocybin therapy?

No — as of 2026, no major US insurer covers psilocybin-assisted therapy. Psilocybin remains Schedule I at the federal level, which means it has no FDA-approved indication and no reimbursement pathway under standard insurance. In Oregon, psilocybin service center sessions ($1,500–$3,500) are entirely out-of-pocket. In Colorado, similar pricing applies. Clinical trials are a free exception — if you qualify for a psilocybin clinical trial, all sessions are provided at no cost. OOTWOracle predicts that if FDA approves psilocybin for TRD (projected NDA Q3 2026), major insurance coverage could follow within 12–24 months of approval — likely with prior authorization requirements similar to Spravato.

Can I use FSA or HSA money for psychedelic therapy?

FSA (Flexible Spending Account) and HSA (Health Savings Account) dollars can be used for many mental health expenses. For psychedelic therapies: Spravato sessions in a clinical setting: Yes — FSA/HSA eligible as it is an FDA-approved treatment administered in a medical setting. IV ketamine infusions: Often yes, if ordered by a physician for a diagnosed medical condition (even off-label). The key is having a Letter of Medical Necessity (LMN) from your prescriber. Oregon/Colorado psilocybin service center sessions: Currently no — there is no FDA approval, and the IRS requires a medical condition and physician recommendation for FSA/HSA eligibility. This may change if psilocybin receives FDA approval. Therapy sessions (preparation, integration): Yes — therapy with a licensed provider is FSA/HSA eligible regardless of whether it involves a psychedelic compound.

How do I get insurance to cover ketamine or Spravato?

For Spravato: (1) Get diagnosed with treatment-resistant depression (TRD) — typically defined as failing 2+ antidepressants. (2) Obtain a prior authorization from your psychiatrist citing the TRD diagnosis and failed prior treatments. (3) Ensure Spravato is on your insurer's formulary — most major plans include it. (4) Treatment must be administered in a certified healthcare setting (not at home). For IV ketamine: (1) Have your psychiatrist write a Letter of Medical Necessity (LMN) documenting TRD, failed prior treatments, and clinical rationale for off-label IV ketamine. (2) Submit a prior authorization request citing CRPS (chronic regional pain syndrome — one of ketamine's FDA-approved indications) if applicable, or cite off-label use for TRD. (3) If denied, file an appeal — see below. (4) If appeal fails, consider Spravato instead, which is covered.

When will insurance cover psilocybin therapy?

OOTWOracle predicts: 67% probability that at least one major US insurer (Aetna, BCBS, UnitedHealth, Cigna, Humana) covers FDA-approved psilocybin for TRD with prior authorization by 2028. The trigger is FDA approval, which is expected in Q4 2026–Q1 2027 based on COMPASS Pathways' NDA timeline. Once approved, insurers typically take 12-18 months to add a new drug to formularies. Psilocybin coverage may initially mirror Spravato's coverage: prior authorization required, clinical setting mandatory, mental health parity laws apply. Full broad coverage (without onerous prior auth) could take until 2030. Medicare and Medicaid coverage timelines lag private insurance by 1-2 years.

What if my insurance denies coverage for ketamine or psychedelic therapy?

Step 1 — Internal appeal: Every insurer must offer an internal appeal process. Obtain the denial letter with the specific denial reason (usually 'not medically necessary' or 'experimental'). Have your prescriber write a detailed appeal letter citing: your specific diagnosis, all failed prior treatments, clinical evidence supporting the requested treatment, and medical necessity documentation. Step 2 — External appeal: If internal appeal fails, request an independent medical review (IMR) — this is a legal right under ACA. An independent reviewer (not employed by your insurer) evaluates your case. Ketamine appeals have a meaningful success rate when well-documented. Step 3 — Mental health parity: Under the Mental Health Parity and Addiction Equity Act (MHPAEA), insurers cannot apply more restrictive coverage limits to mental health conditions than to comparable medical conditions. If your insurer covers experimental cancer treatments but not ketamine for TRD, this may be a parity violation worth challenging.

Does Insurance Cover Psychedelic Therapy? 2026 Coverage Guide

Quick answer table: Scroll down to see the full per-insurer breakdown, FSA/HSA guide, and appeal process. The landscape is changing fast — bookmark this page.

Coverage Status at a Glance (2026)

💊 Spravato (Esketamine)

Covered — Most Plans

FDA-approved nasal spray (Janssen). Covered by Medicare, Medicaid, Aetna, BCBS, Cigna, UnitedHealthcare, Humana with prior authorization for treatment-resistant depression (TRD). Must be administered in certified healthcare setting. Copay typically $0–$50 with coverage; $800–$1,200 per session without.

💉 IV Ketamine Infusions

Partial — With Appeal

NOT FDA-approved for depression — administered off-label. Most plans don't cover it automatically. However, appeals succeed with Letter of Medical Necessity documenting TRD + failed prior treatments. Out-of-pocket: $400–$800/infusion, typically 6 needed. Some plans cover for CRPS (FDA-approved pain indication).

🍄 Psilocybin Therapy

Not Covered — Yet

No coverage from any US insurer in 2026. Still Schedule I federally. Oregon service centers ($1,500–$3,500) and Colorado healing centers are entirely out-of-pocket. Clinical trials are free. Expected to change 12–18 months after FDA approval — Oracle puts approval at 78% probability.

💊 MDMA-Assisted Therapy

Not Covered

FDA rejected MAPS' MDMA PTSD application in August 2024 (CRL). Re-submission ongoing with additional data. No coverage until FDA approval — Oracle gives 38% probability by 2028. When approved, likely to be covered under mental health parity for PTSD indication.

🌿 Ibogaine

Not Covered

Schedule I in US; no FDA approval. No insurance coverage. International treatment centers ($5,000–$20,000) entirely out-of-pocket. VA-funded research trials are free for qualifying veterans. Some nonprofit programs offer subsidized access.

🧠 Therapy Sessions (Integration)

Usually Covered

Preparation and integration therapy with a licensed mental health provider is covered under standard mental health benefits — regardless of whether the sessions involve psychedelics. Under ACA mental health parity, this must be covered comparably to physical health. Your copay applies (typically $20–$60/session).

Insurer-by-Insurer: Spravato Coverage (2026)

Insurer	Spravato Covered?	Prior Auth Required?	Notes
Medicare Part D	Yes	Yes	REMS certification required for facility. TRD diagnosis + failed 2 antidepressants required.
Medicaid	State-dependent	Yes	Most states cover. Verify your state's drug formulary. Some require step therapy (must try cheaper alternatives first).
Aetna	Yes	Yes	Covers for TRD and MDD with suicidal ideation (SI). Quantity limits apply.
Blue Cross Blue Shield	Yes	Yes	Coverage varies by local plan. National BCBS covers TRD indication. Check your specific plan.
UnitedHealthcare	Yes	Yes	Covered under UHC mental health formulary. PA requires documented TRD + failed prior therapies.
Cigna	Yes	Yes	Covers for FDA-approved indications. Step therapy may be required.
Humana	Yes	Yes	Covered with prior authorization for TRD.
Anthem	Yes	Yes	Covers for TRD indication per CMS guidelines.
Kaiser Permanente	Varies by region	Yes	Some KP regions have integrated Spravato clinics. Others require referral. Check your regional plan.

IV Ketamine: How to Get Coverage

IV ketamine infusions are one of the most effective treatments for treatment-resistant depression and suicidal ideation — but most insurers don't automatically cover them because ketamine lacks FDA approval specifically for depression. The pathway to coverage requires strategic documentation.

Step-by-Step Prior Authorization Strategy

Get a formal TRD diagnosis

Treatment-resistant depression (TRD) = typically failing 2+ adequately dosed antidepressants. Document this in your psychiatric records with specific drug names, doses, and durations. This is the foundation of any insurance argument.

Get a Letter of Medical Necessity (LMN)

Your psychiatrist writes a detailed letter documenting: diagnosis, treatment history (all failed medications), functional impairment, clinical rationale for IV ketamine, and why Spravato is not appropriate (if applicable). The more specific, the better — cite published clinical evidence.

File the prior authorization

Submit through your insurer's portal or fax line. Include the LMN, your psychiatric records documenting TRD, and peer-reviewed literature supporting IV ketamine for TRD (the NEJM Esketamine papers, Murrough et al. 2013, etc.).

Appeal a denial immediately

Most initial PA requests are denied. This is expected — don't stop. File an internal appeal within 60 days of denial. Your psychiatrist can call the insurer's peer-to-peer review line to speak directly with the medical reviewer — this significantly improves success rates.

Request external independent review

If internal appeal fails, you have a legal right to an Independent Medical Review (IMR) under ACA. The external reviewer is not employed by your insurer and must apply objective medical standards. Ketamine appeals through IMR succeed in a significant portion of cases.

Mental Health Parity challenge

Under MHPAEA, if your insurer covers off-label treatments for physical conditions (e.g., off-label chemotherapy agents) but not off-label ketamine for TRD, this may violate mental health parity law. Your state insurance commissioner can investigate parity violations. Some patient advocates specialize in parity complaints.

FSA and HSA Eligibility

Treatment	FSA Eligible?	HSA Eligible?	Key Requirement
Spravato sessions	Yes	Yes	FDA-approved treatment; standard eligibility
IV ketamine infusions (with LMN)	Yes	Yes	Letter of Medical Necessity from physician documenting medical condition
Integration therapy (licensed therapist)	Yes	Yes	Licensed mental health provider, diagnosed condition
Oregon psilocybin service centers	No	No	Not FDA-approved; no physician involvement required under OR law
Colorado healing centers	No	No	Same as Oregon — no FDA approval yet
Clinical trial participation	N/A	N/A	Free to participants — no FSA/HSA needed
Travel to treatment (documented medical)	Yes	Yes	Travel to receive eligible medical treatment is FSA/HSA eligible at IRS mileage rate

Pro tip — maximize your FSA/HSA: If you're pursuing IV ketamine treatment out-of-pocket, get a Letter of Medical Necessity first. This makes the infusions FSA/HSA eligible, effectively giving you a 20-37% discount (depending on your tax bracket) on the full cost. For a 6-infusion course at $600/infusion ($3,600 total), that's $720–$1,332 in tax savings.

What to Do Right Now: Decision Tree

Your Situation	Best Coverage Path
Major depression, failed 2+ antidepressants	Try Spravato first — it's covered by most insurers and gives access to a ketamine-based treatment within the insurance system
PTSD, failed multiple treatments	Spravato (covered) or IV ketamine with LMN (appeal). Consider enrolling in MDMA or psilocybin clinical trial (free) while awaiting FDA approval.
Want psilocybin specifically	Clinical trial (free, safest) or out-of-pocket Oregon/Colorado service center. FSA/HSA will not cover yet. Tax deduction for medical expenses over 7.5% of AGI may apply if recommended by physician.
Addiction (AUD, OUD, smoking)	Psilocybin clinical trial (free, several active). IV ketamine + LMN (sometimes covered for comorbid depression). Insurance covers standard addiction treatment (not psychedelic).
End-of-life / existential distress	Oregon/Colorado psilocybin service centers (out-of-pocket) or psilocybin clinical trial. Hospice mental health coverage (standard therapy) is covered separately.
Veteran with PTSD or TBI	VA covers Spravato. VA does NOT yet cover IV ketamine or psychedelics. VA-funded ibogaine and psilocybin trials are free. State veteran programs (TX, CO) may offer additional resources.

Oracle Predictions: When Will Coverage Expand?

67%

At least one major insurer (Aetna, BCBS, UHC, Cigna, Humana) covers FDA-approved psilocybin for TRD by 2028

45%

Medicare covers FDA-approved psilocybin for TRD by 2029

38%

A state legislature passes a psychedelic therapy insurance mandate by 2028

52%

IV ketamine gains formal FDA approval for depression (not just CRPS) enabling standard coverage by 2028

29%

Oregon or Colorado passes legislation requiring insurance coverage of licensed psilocybin service centers by 2029

84%

MDMA-assisted therapy receives FDA approval and insurance coverage framework by 2030

Financial Assistance Programs (When Insurance Falls Short)

Program	What It Covers	How to Apply
Janssen Patient Assistance (Spravato)	Free or reduced-cost Spravato for uninsured/underinsured	JanssenCarePath.com; income-based eligibility
MAPS Patient Access Fund	Subsidized MDMA therapy for Veterans and underserved populations	MAPS.org patient access programs
Heroic Hearts Project	Subsidized ibogaine and psilocybin access for Veterans	HeroicHeartsProject.org
VETS (Veterans Exploring Treatment Solutions)	Ibogaine + 5-MeO-DMT therapy in Mexico for Veterans	VETSolutions.org; based on financial need
Alma Mater Psilocybin	Reduced-cost Oregon service center access	Various OR service centers — ask about sliding-scale fees
Clinical Trials (ClinicalTrials.gov)	Free psilocybin, MDMA, ketamine, ibogaine sessions	Search by compound and diagnosis at ClinicalTrials.gov
Medical expense deduction (IRS)	Out-of-pocket mental health expenses exceeding 7.5% of AGI	Schedule A itemized deduction; requires physician recommendation

Frequently Asked Questions

It depends on the form. Spravato (esketamine nasal spray) is FDA-approved and covered by most major insurers — Medicare, Medicaid, Aetna, BCBS, UHC, Cigna, Humana — with prior authorization for treatment-resistant depression. IV ketamine infusions are administered off-label and typically not covered automatically. However, with a Letter of Medical Necessity documenting TRD and failed prior treatments, prior authorization appeals succeed in a meaningful percentage of cases. IV ketamine typically costs $400–$800/infusion out-of-pocket.

No — not yet. As of 2026, psilocybin remains Schedule I and has no FDA-approved indication in the US. No insurer covers Oregon or Colorado psilocybin service center sessions. The path to coverage runs through FDA approval — which the Oracle gives 78% probability, potentially Q4 2026. Once approved, insurers typically take 12–18 months to add coverage. Psilocybin therapy will likely initially look like Spravato's coverage: prior authorization required, clinical setting mandatory, mental health parity applied.

For Spravato: yes, FSA/HSA eligible as FDA-approved treatment. For IV ketamine: yes, with a Letter of Medical Necessity from your physician. For Oregon/Colorado psilocybin service centers: no, not currently — no FDA approval means no FSA/HSA eligibility. For preparation and integration therapy with a licensed therapist: yes, FSA/HSA eligible under standard mental health coverage. If ketamine or psilocybin receives FDA approval, FSA/HSA eligibility would follow automatically.

For Spravato: (1) Get diagnosed with TRD (failed 2+ antidepressants). (2) Have your psychiatrist submit prior authorization with TRD documentation. (3) Treatment must be in a certified clinical setting. For IV ketamine: (1) Get a Letter of Medical Necessity documenting TRD and failed treatments. (2) Submit prior authorization — expect initial denial. (3) File an internal appeal; have your psychiatrist request a peer-to-peer review call with the insurer's medical reviewer. (4) If denied, request independent external review (legal right under ACA). (5) Cite mental health parity law if insurer covers comparable off-label physical treatments.

OOTWOracle gives 67% probability that at least one major insurer covers FDA-approved psilocybin for TRD by 2028. The trigger is FDA approval — expected NDA submission Q3 2026, approval window Q4 2026–Q1 2027 based on COMPASS Pathways' timeline. After FDA approval, insurers typically add new therapies to formularies in 12–18 months. Medicare/Medicaid coverage lags private insurance by 1–2 years. Oregon/Colorado coverage mandates would require state legislation — Oracle gives this 29% probability by 2029.

Step 1: File an internal appeal within 60 days — include a detailed Letter of Medical Necessity and clinical evidence citations. Have your psychiatrist request a peer-to-peer review with the insurer's medical reviewer. Step 2: If internal appeal fails, request an Independent Medical Review (IMR) — you have a legal right to this under ACA. Step 3: File a mental health parity complaint with your state insurance commissioner if the denial seems discriminatory compared to comparable physical health treatment coverage. Step 4: Consider Spravato as an alternative — it's covered and is a ketamine-based treatment. Financial assistance programs exist for those who can't access insurance coverage.

Related Resources

🔮 OOTWOracle tracks insurance coverage signals daily

8 AI agents monitoring FDA decisions, CMS reimbursement signals, state legislation, and insurer formulary changes — providing daily confidence-scored predictions on when psychedelic therapy coverage arrives at scale.

View Today's Oracle Report →

Does Insurance Cover Psychedelic Therapy? 2026 Complete Guide